Milestone Pharmaceuticals Launches CARDAMYST Nasal Spray in US Market for PSVT

summarizeSummary

Milestone Pharmaceuticals announced the commercial availability of CARDAMYST (etripamil) nasal spray in the U.S., marking the launch of its first FDA-approved self-administered treatment for PSVT.

check_boxKey Events

• CARDAMYST Now Available in U.S.

  Milestone Pharmaceuticals Inc. announced the U.S. availability of CARDAMYST (etripamil) nasal spray through retail pharmacies, effective January 26, 2026.

• First Self-Administered PSVT Treatment

  CARDAMYST is the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia (PSVT), addressing a significant patient population.

• Commercialization Strategy Underway

  A national sales force will be deployed in mid-February 2026, supported by a patient assistance program designed to cap copays at $25 for eligible commercially insured patients.

• Follows Recent Regulatory Milestones

  This commercial launch follows the FDA approval of CARDAMYST on December 12, 2025, and the EMA's acceptance of its Marketing Authorization Application on January 6, 2026.

auto_awesomeAnalysis

This 8-K filing announces the commercial availability of CARDAMYST (etripamil) nasal spray in the U.S., marking a pivotal transition for Milestone Pharmaceuticals from a development-stage company to a commercial entity. The product, the first and only FDA-approved self-administered treatment for paroxysmal supraventricular tachycardia (PSVT), addresses a significant unmet medical need for an estimated two million patients. The company's immediate commercialization plan, including a national sales force and patient assistance programs, is crucial for market penetration and revenue generation, building upon the FDA approval received in December 2025. This event is critical for the company's long-term financial performance and growth prospects.